Overview

Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate

Status:
Withdrawn
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Ghent
Collaborators:
MEDA Pharma GmbH & Co. KG
University of Wuerzburg
Treatments:
Fluticasone
Xhance